Live Breaking News & Updates on அமரின் மருந்துகள் ஐயர்ல்யாஂட் லிமிடெட்

Stay updated with breaking news from அமரின் மருந்துகள் ஐயர்ல்யாஂட் லிமிடெட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Hikma Should Face Amarin's Patent Suit, Magistrate Says

Law360
ADVERTISEMENT
Hikma Should Face Amarin s Patent Suit, Magistrate Says
Law360 (August 3, 2021, 8:54 PM EDT) Hikma Pharmaceuticals should not be able to dodge a lawsuit claiming it encouraged doctors to prescribe its generic version of the heart drug Vascepa for uses covered by a series of Amarin patents, a Delaware federal magistrate judge says.
Magistrate Judge Jennifer L. Hall on Tuesday issued a report and recommendation in a lawsuit filed by Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Ltd. and Mochida Pharmaceutical Co. Ltd. alleging that Hikma induced infringement of three patents.
Specifically, Amarin alleged in the so-called skinny label case that Hikma induced doctors to infringe the patents by instructing them to use the Hikma generic. ....

United States , Jenniferl Hall , Mochida Pharmaceutical Co , Amarin Pharma Inc , Amarin Pharmaceuticals Ireland Ltd , Hikma Pharmaceuticals , Judge Jennifer , Amarin Pharmaceuticals Ireland , Mochida Pharmaceutical , ஒன்றுபட்டது மாநிலங்களில் , அமரின் பார்மா இன்க் , அமரின் மருந்துகள் ஐயர்ல்யாஂட் லிமிடெட் , ஹிக்மா மருந்துகள் , நீதிபதி ஜெனிபர் , அமரின் மருந்துகள் ஐயர்ல்யாஂட் ,

President Biden Signs Legislation Boosting Generic and Biosimilar Drugs to Help Foster Price Competition | White & Case LLP

To embed, copy and paste the code into your website or blog:
On April 23, 2021, President Biden signed into law two bipartisan bills aimed at reducing prescription drug prices by supporting generic and biosimilar alternatives to branded drugs.
The Ensuring Innovation Act supports generic drugs by clarifying the technical qualifications for earning exclusivity as a new chemical entity. The Advancing Education on Biosimilars Act provides for increased federal efforts to educate patients, doctors and caregivers about biosimilar drugs.
These changes come as proposals for more comprehensive legislation on drug pricing, such as allowing Medicare to negotiate prices directly with manufacturers, have thus far been excluded from the Biden Administration’s major spending initiatives. Below is a short summary of each new bill. ....

New York , United States , District Of Columbia , White House , Amarin Pharm , Shravya Govindgari White , Amarin Vascepa , Us District Court , Drug Administration , Amarin Pharmaceuticals Ireland Ltd , Biden Administration , Amarin Corp , White Case , President Biden , Ensuring Innovation Act , Advancing Education , Biosimilars Act , Amarin Pharmaceuticals Ireland , Biologics Price Competition , Innovation Act , American Rescue Plan , American Jobs Plan , Americas Family , Amarin Announces , Chemical Entity Exclusivity Determination , American Rescue Plan Act ,